Article Watch, December 2013

Antibodies to watch in 2013

The transitions of antibody therapeutics to late-stage clinical development, regulatory review and the market are proceeding at a rapid pace in 2013. Since late 2012, two monoclonal antibody (mAb) therapeutics (itolizumab, trastuzumab emtansine) received their first approvals, first marketing applications for three mAbs (vedolizumab, ramucirumab, obinutuzumab) were submitted to regulatory agenc...

Board walk - December 2013.

Dear colleagues, It is a singular honor and tremendous privilege to have been elected President-elect by the International Headache Society members. The opportunity to work alongside remarkably accomplished leaders in the field on the board is not only humbling, but comforting, knowing that the society is in such wise and capable hands. I have a long history of service to the International Head...

Cover vol. 10, no. 6, December 2013

News and Views–December 2013

News and Views is the newsletter of the British Nuclear Medicine Society. It comprises articles and up to date, relevant information for those working within the nuclear medicine community both nationally and internationally. Readers are invited to submit material, meeting announcements and training opportunities to the Editor: Dr Jim Ballinger, Department of Nuclear Medicine, Guy’s and St Thom...

In the December 2013 issue